Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 101 related to Johnson: Who Is Tested for Diabetic Kidney Disease and Who Initiates Treatment?. (0.09 sec) 

Who Is Tested for Diabetic Kidney Disease and Who Initiates Treatment?


SL Johnson, EF Tierney, KU Onyemere, CW Tseng, … - Diabetes care, 2006 - Am Diabetes Assoc
RESULTS—At baseline, 52% of patients not receiving ACE inhibitor/ARB therapy and without known
diabetic kidney disease (DKD) were screened for albuminuria. Patients ≥65 years of age, those with
higher HbA 1c , those with ...
Cited by 1 - Related articles - BL Direct - All 6 versions

Clinical testing patterns and cost implications of variation in the evaluation of CKD …


RF Charles, NR Powe, BG Jaar, MU Troll, RS … - American Journal of …, 2009 - Elsevier
Clinical practice guidelines were established to improve the diagnosis and management of chronic
kidney disease (CKD), but the extent, determinants, and cost implications of guideline adherence and
variation in adherence have not ...
Cited by 1 - Related articles - All 21 versions

Use of microalbuminuria testing in persons with type 2 diabetes: are the right …


WJ Hueston, S Scibelli, III Mainous - The Journal of family practice, 2001 - ncbi.nlm.nih.gov
OBJECTIVE: Our goal was to determine whether adult patients with type 2 diabetes who had gross
proteinuria or were already taking angiotensin-blocking drugs were screened for microalbuminuria.
STUDY DESIGN: This was a ...
Cited by 10 - Related articles - BL Direct - All 2 versions

[CITATION] Consensus statement


W Herman, V Hawthorne, R Hamman, H Keen, R … - Am J Kidney Dis, 1989
Cited by 11 - Related articles

Telmisartan and enalapril in type 2 diabetes: Diabetics Exposed to Telmisartan and …


A Barnett - The British Journal of Diabetes & Vascular Disease, 2005 - dvd.sagepub.com
Page 1. http://dvd.sagepub.com The British Journal of Diabetes & Vascular Disease DOI:
10.1177/14746514050050010501 2005; 5; 24 British Journal of Diabetes & Vascular Disease Anthony Barnett
Telmisartan and enalapril in type 2 diabetes: Diabetics Exposed to Telmisartan and Enalapril (DETAIL) ...
Related articles - All 2 versions

Le point sur le traitement de l'hypertension arterielle: que tirer des grandes etudes …


M Burnier - Médecine et hygiène, 2003 - titan.medhyg.ch
Au cours des deux dernières années, de nombreuses grandes études cliniques, randomisées et
contrôlées ont été publiées dans le domaine de l'hypertension artérielle. Certaines (ALLHAT
par exemple) avaient pour but de ...
Related articles - Cached - BL Direct - All 2 versions

[PDF] DIABETICKÁ NEFROPATIE–NOVÉ MOŽNOSTI LÉČBY


DNNEWPOF THERAPY - internimedicina.cz
Úvod Diabetická nefropatie, zejména na podkladě diabetu 2. ty- pu, představuje narůstající
medicínský a ekonomický problém v zemích západní Evropy (včetně České republiky), USA a
Japonsku. V roce 2000 byla v ...
Related articles - View as HTML - All 4 versions

Antihypertensive treatment and multifactorial approach for renal protection in …

- asnjournals.org
P Fioretto, A Solini - Journal of the American Society of Nephrology, 2005 - Am Soc Nephrol
Type 2 diabetes is reaching epidemic proportions throughout the world, representing the most common
cause of ESRD. Early identification of renal impairment associated with diabetes and initiation of
renoprotective therapy are ...
Cited by 17 - Related articles - All 4 versions

[PDF] Antihypertensive Treatment and Multifactorial Approach for Renal Protection in …


A Treatment - Journal of the American Society of Nephrology, 2005 - Am Soc Nephrol
Type 2 diabetes is reaching epidemic proportions throughout the world, representing the most common
cause of ESRD. Early identification of renal impairment associated with diabetes and initiation of
renoprotective therapy are ...
Related articles

[PDF] Treatment for diabetic nephropathy: angiotensin receptor blockers do not have an …


L Feldman, J Weissgarten - IMAJ-RAMAT GAN-, 2004 - ima.org.il
Page 1. Treatment for Diabetic Nephropathy: Angiotensin Receptor Blockers do not have an
Advantage over Angiotensin-Converting Enzyme Inhibitors Leonid Feldman MD and Joshua
Weissgarten MD Nephrology Division, Assaf Harofeh Medical Center, Zerifin ...
Related articles - View as HTML - BL Direct - All 2 versions


Result Page: 

1

2

3

4

5

6

7

8

9

10

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google